#1 Clinical Trials Search in Europe

Olaptesed Pegol

Olaptesed Pegol, also known as NOX-A12, is an innovative drug being investigated in clinical trials for its potential in treating various types of cancer. This article explores the use of Olaptesed Pegol in clinical trials, focusing on its application in colorectal cancer, pancreatic cancer, and glioblastoma. We’ll discuss how this drug works, its combination with other treatments, and the ongoing research to evaluate its safety and efficacy.

Table of Contents

What is Olaptesed Pegol?

Olaptesed Pegol, also known as NOX-A12, is an experimental drug being studied for its potential in treating various types of cancer[1]. It’s a new type of medication that works differently from traditional chemotherapy drugs. Researchers are excited about its potential to make other cancer treatments work better.

How Does It Work?

Olaptesed Pegol targets a specific molecule in the body called CXCL12. This molecule plays a crucial role in how cancer cells interact with their surroundings. By blocking CXCL12, Olaptesed Pegol aims to change the tumor microenvironment – the area immediately surrounding the tumor[1]. The goal is to make the cancer more vulnerable to other treatments, especially a type of therapy called immunotherapy, which helps the body’s own immune system fight cancer.

What Cancers Does It Treat?

Olaptesed Pegol is being studied in several types of cancer, including:

  • Metastatic Colorectal Cancer: Cancer of the colon or rectum that has spread to other parts of the body[1]
  • Metastatic Pancreatic Cancer: Cancer of the pancreas that has spread to other areas[1][2]
  • Glioblastoma: A type of aggressive brain cancer[3]

Clinical Trials

Olaptesed Pegol is currently being tested in several clinical trials. These are research studies that help doctors understand how well a new treatment works and if it’s safe. Some key points about these trials include:

  • Different doses are being tested to find the most effective and safe amount[3]
  • The drug is being studied both alone and in combination with other cancer treatments[1][2]
  • Researchers are looking at how the drug affects the cancer environment and the patient’s immune response[1]
  • The trials are measuring things like how long patients live without their cancer getting worse (progression-free survival) and overall survival rates[2][3]

Combination Therapies

One of the most promising aspects of Olaptesed Pegol is its potential to work well with other cancer treatments. It’s being studied in combination with:

  • Pembrolizumab (also known as Keytruda): An immunotherapy drug that helps the immune system recognize and attack cancer cells[1][2]
  • Radiation therapy: Uses high-energy rays to kill cancer cells[3]
  • Chemotherapy drugs: Such as nanoliposomal irinotecan, 5-FU, leucovorin, gemcitabine, and nab-paclitaxel[2]
  • Bevacizumab: A drug that affects blood vessel growth in tumors[3]

Side Effects and Safety

As with any new drug, understanding the side effects and safety of Olaptesed Pegol is a crucial part of the research. The clinical trials are closely monitoring patients for any adverse reactions. This includes checking:

  • Vital signs like pulse rate and blood pressure
  • Heart function through ECGs
  • Blood tests to check for effects on blood cells and other body systems
  • Any other unexpected side effects[1]

It’s important to note that as Olaptesed Pegol is still in the testing phase, not all potential side effects may be known yet.

Future Prospects

The research on Olaptesed Pegol is ongoing, and it’s too early to say for certain how effective it will be. However, researchers are hopeful about its potential, especially in making other cancer treatments more effective. If the clinical trials show good results, it could lead to new treatment options for patients with hard-to-treat cancers[1][2][3]

As research continues, more information will become available about how well Olaptesed Pegol works and its safety profile. Patients interested in this treatment should discuss it with their oncologist to understand if participating in a clinical trial might be an option for them.

Aspect Details
Drug Name Olaptesed Pegol (NOX-A12)
Mechanism of Action Targets and inactivates CXCL12 in the tumor microenvironment
Cancer Types Studied Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Glioblastoma
Combination Therapies Pembrolizumab, Radiation Therapy, Chemotherapy (e.g., nanoliposomal irinotecan, gemcitabine, nab-paclitaxel)
Administration Intravenous infusion, various dosages (200mg, 400mg, 600mg) and schedules
Primary Outcomes Measured Safety, Pharmacodynamics, Disease Control Rate
Secondary Outcomes Progression-free Survival, Overall Survival, Response Rates, Quality of Life
Current Status In Phase 1/2 and Phase 2 clinical trials

FAQ

  • What is Olaptesed Pegol and how does it work? Olaptesed Pegol, also known as NOX-A12, is a drug that targets a key chemokine called CXCL12 in the tumor microenvironment. It works by inactivating CXCL12, which is involved in cancer cell communication and resistance to certain treatments. By blocking CXCL12, Olaptesed Pegol may make tumors more susceptible to other cancer treatments, particularly immunotherapies.
  • In which types of cancer is Olaptesed Pegol being studied? Olaptesed Pegol is being studied in clinical trials for several types of cancer, including metastatic colorectal cancer, metastatic pancreatic cancer, and glioblastoma (a type of brain cancer).
  • How is Olaptesed Pegol administered to patients? Olaptesed Pegol is typically administered intravenously (through a vein). The dosage and frequency can vary depending on the specific clinical trial and treatment plan. In some studies, it is given as a continuous infusion, while in others, it may be administered weekly or at other intervals.
  • Is Olaptesed Pegol used alone or in combination with other treatments? Olaptesed Pegol is being studied both as a monotherapy (used alone) and in combination with other treatments. Many trials are exploring its use in combination with immunotherapy drugs like pembrolizumab, as well as with standard chemotherapy drugs and radiation therapy.
  • What are the potential benefits of Olaptesed Pegol in cancer treatment? The potential benefits of Olaptesed Pegol include making tumors more responsive to immunotherapy, improving the effectiveness of other cancer treatments, and potentially increasing survival rates for patients with hard-to-treat cancers. However, it's important to note that as the drug is still in clinical trials, its full benefits and risks are still being evaluated.

Ongoing Clinical Trials on Olaptesed Pegol

  • Study on Glioblastoma Treatment with Olaptesed Pegol and Radiation, with Bevacizumab or Pembrolizumab, for Patients with Unmethylated MGMT Promoter

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Olaptesed Pegol: A drug that targets and inactivates CXCL12, a key chemokine in the tumor microenvironment, potentially making tumors more susceptible to other cancer treatments.
  • CXCL12: A chemokine (signaling protein) involved in cancer cell communication and resistance to certain treatments. It's the target of Olaptesed Pegol.
  • Tumor microenvironment: The area surrounding a tumor, including blood vessels, immune cells, and signaling molecules, which can influence tumor growth and response to treatment.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer cells.
  • Pembrolizumab: An immunotherapy drug that helps the immune system detect and fight cancer cells.
  • Metastatic: Cancer that has spread from its original site to other parts of the body.
  • Glioblastoma: An aggressive type of cancer that occurs in the brain or spinal cord.
  • MGMT promoter: A genetic marker that can indicate how well a glioblastoma might respond to certain treatments.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Overall survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • Disease control rate (DCR): The percentage of patients whose cancer shrinks or remains stable in response to treatment.
  • Adverse events: Unexpected medical problems that happen during treatment with a drug or other therapy.

References